December 17, 2025: Federal Litigation Created for People Who Lost Their Vision After Taking Ozempic On December 15, 2025, the Joint Panel on Multidistrict Litigation (JPML) approved a request to consolidate lawsuits filed by people who experienced vision loss after taking Ozempic and other GLP-1 drugs
Semaglutide, a long-acting GLP-1 analogue, for the management of early-onset obesity due to MC4R defect: A case report
If over 40 cm (16 in) projected adult diameter with hypertrichosis, it is sometimes called giant hairy nevus
However, blood is infrequently recognized, and neutrophils are typically present in only small numbers in normal secretions
For everyday use, oral glutathione is one of the safest and most practical choices
As seen in Figure 3 , several risk factors were put out as potential causes of intestinal dysbiosis